Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

Oncogene

Volumn 32, Issue 25, 2013, Pages 3091-3100

  Wang, P ^a,b   Dong, Q ^b   Zhang, C ^c   Kuan, P F ^d,e   Liu, Y ^c   Jeck, W R ^e,f   Andersen, J B ^g   Jiang, W ^a,b   Savich, G L ^e,f   Tan, T X ^e,f   Auman, J T ^e   Hoskins, J M ^e   Misher, A D ^e   Moser, C D ^h   Yourstone, S M ^e,f   Kim, J W ⁱ   Cibulskis, K ^j   Getz, G ^j   Hunt, H V ^f   Thorgeirsson, S S ^g   Roberts, L R ^h   Ye, D ^b   Guan, K L ^a,b,k   Xiong, Y ^a,b,e,f   Qin, L X ^b   Chiang, D Y ^e,f   more..

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c University of North Carolina at Chapel Hill   (United States)

^d IL   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h MAYO CLINIC CANCER CENTER   (United States)

ⁱ WAKE FOREST BAPTIST HEALTH   (United States)

^j BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

DNA methylation; epigenetics; tumor metabolism

Indexed keywords

HISTONE H3; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; PROTEIN P53;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER RECURRENCE; CANCER SURGERY; CPG ISLAND; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GLIOBLASTOMA; HISTONE METHYLATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; STRESS; TRANSCRIPTION INITIATION SITE;

BASE SEQUENCE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BRAIN NEOPLASMS; CHOLANGIOCARCINOMA; CPG ISLANDS; DNA METHYLATION; GLIOBLASTOMA; HISTONES; HUMANS; ISOCITRATE DEHYDROGENASE; LIVER NEOPLASMS; MUTATION; NEOPLASM RECURRENCE, LOCAL; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84879418850     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.315     Document Type: Article

References (46)

1. Yan H, Parsons DW, Jin GL, McLendon R, Rasheed BA, Yuan WS et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
2. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2010; 28: 2348-2355.
3. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011; 224: 334-343.
4. Shibata T, Kokubu A, Miyamoto M, Sasajima Y, Yamazaki N. Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am J Pathol 2011; 178: 1395-1402.
5. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 2011; 43: 1262-1265.
6. Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011; 43: 1256-1261.
7. Zhao SM, Lin Y, Xu W, Jiang WQ, Zha ZY, Wang P et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 alpha. Science 2009; 324: 261-265.
8. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-744.
9. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH et al. Oncometabolite 2-hydro-xyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19: 17-30.
10. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoeitic differentiation. Cancer Cell 2010; 18: 553-567.
11. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324: 930-935.
12. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466: 1129-1133.
13. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011; 333: 1300-1303.
14. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q et al. Tet-mediated formation of 5-car-boxylcytosine and its excision by TDG in mammalian DNA. Science 2011; 333: 1303-1307.
15. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP et al. Identification of a CpG Island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17: 510-522.
16. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2009; 17: 98-110.
17. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
18. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96: 8681-8686.
19. Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 2004; 22: 4584-4594.
20. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692.
21. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C et al. Epigenetic stem cell signature in cancer. Nature Genet 2007; 39: 157-158.
22. Ohm JE, McGarvey KM, Yu X, Cheng LZ, Schuebel KE, Cope L et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hyper-methylation and heritable silencing. Nat Genet 2007; 39: 237-242.
23. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007; 39: 232-236.
24. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med 2011; 3: 75ra25.
25. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008; 48: 308-321.
26. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010; 28: 3531-3540.
27. Yang B, Zhong C, Peng YJ, Lai Z, Ding JP. Molecular mechanisms of 'off-on switch' of activities of human IDH1 by tumor-associated mutation R132H. Cell Res 2010; 20: 1188-1200.
28. Xu Y, Wu F, Tan L, Kong L, Xiong L, Deng J et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 2011; 42: 451-464.
29. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012; 26: 756-784.
30. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174: 1149-1153.
31. Aishima S, Kuroda Y, Nishihara Y, Taguchi K, Taketomi A, Maehara Y et al. Gastric mucin phenotype defines tumour progression and prognosis of intrahepatic cholangiocarcinoma: gastric foveolar type is associated with aggressive tumour behaviour. Histopathology 2006; 49: 35-44.
32. Andersen JB, Spee B, Bechacz BR, Avital I, Komuta M, Barbour A et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012; 142: 1021-1031.
33. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangio-carcinoma identified through broad-based tumor genotyping. Oncologis 2012; 17: 72-79.
34. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neo-morphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234.
35. Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, Zhang L et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol 2012.
36. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011; 20: 11-24.
37. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao JJ, Hedvat C et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010; 70: 447-452.
38. Turner R, Lozoya O, Wang Y, Cardinale V, Gaudio E, Alpini G et al. Human hepatic stem cell and maturational liver lineage biology. Hepatology 2011; 53: 1035-1045.
39. Cardinale V, Wang Y, Carpino G, Mendel G, Alpini G, Gaudio E et al. The biliary tree-a reservoir of multipotent stem cells. Nat Rev Gastroenterol Hepatol 2012; 9: 231-240.
40. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012; 22: 271-282.
41. Brenet F, Moh M, Funk P, Feierstein E, Viale AJ, Socci ND et al. DNA methylation of the first exon is tightly linked to transcriptional silencing. PLoS One 2011; 6: e14524.
42. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472.
43. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
44. Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D et al. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2010; 2: 54ra77.
45. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
46. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One 2010; 5: e13984.